BioCryst Pharmaceuticals, Inc. (BCRX) 2025 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, and welcome to the BioCryst fourth-quarter 2025 conference call (Operator Instructions) Please note this event is being recorded.

    大家好,歡迎參加 BioCryst 2025 年第四季電話會議(操作說明)。請注意,本次會議正在錄音。

  • I would now like to turn the conference over to Nick Wilder with BioCryst. Please go ahead.

    現在我將把會議交給BioCryst公司的Nick Wilder先生。請開始吧。

  • Nick Wilder - Manager of Investor Relations

    Nick Wilder - Manager of Investor Relations

  • Good morning, and welcome to BioCryst's full year 2025 corporate update and financial results conference call. Participating with me today are President and CEO, Charlie Gayer; Chief Financial Officer, Babar Ghias; and Chief Development Officer, Dr. Bill Sheridan. A press release and slide presentation about today's news are available on our Investor Relations website.

    早安,歡迎參加BioCryst 2025年全年公司發展動態及財務績效電話會議。今天與我一同出席會議的有總裁兼執行長Charlie Gayer、財務長Babar Ghias以及首席發展長Bill Sheridan博士。有關今天新聞的新聞稿和幻燈片簡報已發佈在我們的投資者關係網站上。

  • Today's call may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation.

    今天的電話會議可能包含前瞻性陳述,包括有關未來業績、未經審計的前瞻性財務資訊以及公司未來表現和/或成就的陳述。這些陳述受已知和未知風險及不確定性的影響,可能導致我們的實際業績、表現或成就與本次演示中明示或暗示的任何未來業績或表現存在重大差異。

  • For additional information, including a detailed discussion of these risks, please refer to slide 2 of the presentation. In addition, today's conference call includes non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures against the most directly comparable GAAP financial measure, please refer to the earnings press release available on our Investor Relations website.

    如需了解更多信息,包括對這些風險的詳細討論,請參閱簡報第2頁。此外,今天的電話會議包含非GAAP財務指標。如需了解這些非GAAP財務指標與最直接可比較的GAAP財務指標的調節表,請參閱我們投資者關係網站上發布的獲利新聞稿。

  • I'd now like to turn the call over to Charlie.

    現在我想把電話交給查理。

  • Charles Gayer - President, Chief Executive Officer, Director

    Charles Gayer - President, Chief Executive Officer, Director

  • Thanks, Nick. This is my first earnings call as CEO of BioCryst, and I'm happy about where the company is today and even more excited about our future. We closed 2025 with strong momentum, delivering full-year ORLADEYO revenue of $601.8 million. That was up 38% for the year and 43% when you exclude our Europe business that we sold in October.

    謝謝,尼克。這是我擔任BioCryst執行長的第一次財報電話會議,我對公司目前的狀況感到滿意,對未來更充滿信心。我們在2025年末保持了強勁的成長勢頭,全年ORLADEYO營收達到6.018億美元。這一數字年增38%,如果剔除我們在10月出售的歐洲業務,則較去年同期成長43%。

  • We are also starting 2026 on a high note as we expanded our HAE portfolio with our acquisition of Astra Therapeutics last month. As I step into my new role, I want to be clear about BioCryst's strategy. We are and will remain a profitable rare disease company committed to meeting the unmet needs of patients through commercialization, innovation, and excellence that is backed by well-understood biology and disciplined clinical development.

    2026 年伊始,我們迎來了一個振奮人心的開端:上個月,我們收購了 Astra Therapeutics,進一步拓展了我們的 HAE 產品組合。在我履新之際,我想明確闡述 BioCryst 的策略。我們始終是一家盈利的罕見疾病公司,並將繼續致力於透過商業化、創新和卓越的研發,滿足患者尚未被滿足的醫療需求。而這一切都建立在對生物學的深刻理解和嚴謹的臨床開發之上。

  • Where we will continue to evolve is how focused and explicit we are about capital allocation and accountability. We want to ensure that every dollar we deploy has a clear line of sight to driving long-term value creation. Coming back to our HAE portfolio, we see a tremendous opportunity to build value by meeting the needs of a growing number of HAE patients.

    我們將持續改善的面向在於如何更明確、更清晰地闡述資本配置和問責機制。我們希望確保每一分錢的投入都能清晰地指向長期價值的創造。回到我們的HAE產品組合,我們看到了透過滿足日益增長的HAE患者群體的需求來創造價值的巨大機會。

  • We view HAE not as a winner-take-all efficacy race, but as a structurally segmented market, driven by biology, patient preference, and real-world experience. Rather than a market that resets with every new entrant, we see a market that segments based on the needs of individual patients. We now have a portfolio of differentiated products in ORLADEYO capsules for ages 12 and up, ORLADEYO pellets for younger kids, and a late-stage asset in Navenibart.

    我們認為遺傳性血管性水腫(HAE)並非一場贏家通吃的療效競賽,而是一個結構性細分的市場,其驅動因素包括生物特性、病患偏好和真實世界經驗。我們認為,市場不會隨著每個新進入者的出現而重置,而是基於個別患者的需求進行細分。目前,我們擁有差異化的產品組合,包括適用於12歲及以上族群的ORLADEYO膠囊、適用於較小兒童的ORLADEYO顆粒劑,以及處於後期研發階段的Navenibart。

  • Each of these therapies will allow us to achieve growth and durable revenue within specific segments of the market. ORLADEYO has grown strongly in part because of its differentiation as the oral option. But more importantly, there is a super responder population that can get injectable-like attack control. We saw in our pivotal trial that just over 50% of patients starting on ORLADEYO stayed on for two-years and had a 91% reduction from baseline.

    這些療法中的每一種都將幫助我們在特定的細分市場中實現成長和可持續的收入。 ORLADEYO 的成長勢頭強勁,部分原因在於其作為口服藥物的獨特優勢。但更重要的是,它能為部分患者提供與注射劑相媲美的療效。在我們關鍵性試驗中,超過 50% 的患者在開始使用 ORLADEYO 兩年後仍堅持用藥,且病情較基線水平降低了 91%。

  • In the real world, 60% of patients stay on therapy through 12-months, and nearly 50% of all patients who have tried ORLADEYO in the US over the past five-years are still on therapy. Most ORLADEYO super responders are unlikely to switch even if another oral option reaches the market because their needs are already met.

    在實際應用中,60%的患者能夠堅持治療12個月,過去五年在美國嘗試過ORLADEYO的患者中,近50%仍在接受治療。大多數對ORLADEYO療效顯著的患者即使有其他口服藥物上市,也不太可能更換治療方案,因為他們的需求已經得到滿足。

  • And now we have a new member of the ORLADEYO family. We are excited to launch ORLADEYO pellets for kids ages 2 to under 12 at the Quad AI conference this weekend. The unmet need is significant because HAE and related attacks are underdiagnosed in younger kids, and prophylaxis usage is only half that of adults.

    現在,ORLADEYO家族又添新成員。我們非常興奮地宣布,本週末在Quad AI大會上,我們將推出適用於2歲至12歲以下兒童的ORLADEYO吸入劑。由於遺傳性血管性水腫(HAE)及相關疾病在低齡兒童診斷不足,且預防性用藥率僅為成人的一半,因此,兒童的醫療需求遠未得到滿足。

  • Availability of a safe, effective, and targeted oral prophy has the potential to change how kids with HAE grow up, and ORLADEYO is likely to be the only oral option for several years to come. We think about Navenibart through that same lens of structural differentiation in HAE. Navenibart is not intended to replace ORLADEYO. It is intended to allow BioCryst to address patients' needs across the full spectrum of efficacy, dosing, and convenience preferences in HAE prophylaxis.

    安全、有效且標靶性強的口服預防藥物的出現,有望改變遺傳性血管性水腫(HAE)患兒的成長方式,而ORLADEYO很可能在未來幾年內是唯一的口服選擇。我們從HAE的結構差異角度來考慮Navenibart。 Navenibart並非旨在取代ORLADEYO,而是旨在幫助BioCryst滿足HAE預防治療中患者在療效、劑量和便利性等方面的各種需求。

  • There are approximately 5,000 US patients who have great attack control by injecting anywhere from twice a week to every four-weeks. Most of them are reluctant to take a chance on oral because they are well controlled already, and the injections themselves are not a barrier to treatment. Oral is not their need. But our research shows that many are very attracted to the idea of a simple, high-efficacy injectable dosed just two or four times per year.

    美國約有5000名患者透過每週兩次到每四周一次的注射治療,病情得到了很好的控制。他們中的大多數人不願意嘗試口服藥物,因為他們的病情已經得到了很好的控制,而且注射本身對他們來說也不是治療的障礙。口服藥物並非他們的需求。但我們的研究表明,許多患者非常青睞這種簡單且高效、每年只需注射兩到四次的治療方案。

  • That is a leap patients dosing an injectable 12, 26, or even over 100 times per year are likely to make because it aligns with what they know and provides something better. Our objective is to keep the HAE prophylaxis treatment decisions within the BioCryst portfolio. That is another way we think about long-term durability, not as defending a single product, but as owning the prophy decision framework in HAE.

    對於每年需要注射12次、26次甚至100多次的患者來說,這無疑是一個巨大的飛躍,因為這符合他們已有的認知,並且能夠提供更好的治療方案。我們的目標是確保HAE預防性治療方案的決策權始終掌握在BioCryst的產品組合之內。這反映了我們對長期發展前景的另一種理解:並非僅僅捍衛單一產品,而是掌控HAE預防性治療的決策架構。

  • We will offer three compelling options, all from a team that the HAE community knows and trusts. Before turning to Bill, I want to briefly touch on BCX17725, our early-stage program in Netherton syndrome. This is a classic rare disease story - a devastating genetic condition that is underdiagnosed because there are no good treatment options.

    我們將提供三種極具吸引力的方案,所有方案均出自HAE社群熟悉且信賴的團隊。在Bill發言之前,我想先簡單介紹BCX17725,這是我們針對內瑟頓症候群的早期研發計畫。這是一個典型的罕見疾病案例——一種毀滅性的遺傳性疾病,由於缺乏有效的治療方案,常常被漏診。

  • We are encouraged by the results in healthy volunteers and the investigator's enthusiasm for this program. We're on a path to generate clinical data in patients by the end of the year, and we'll use that evidence plus feedback from patients and investigators to guide next steps. Looking ahead to 2026 and beyond, we see durable revenue growth anchored by a skilled, motivated and resilient commercialization team, meeting the needs of adults and kids who want oral HAE prophylaxis, a second molecule advancing well in late-stage development that has the potential to lead the injectable prophylaxis segment and additional rare disease optionality in our pipeline, positioning BioCryst for sustained value creation.

    我們對健康志願者的研究結果以及研究人員對該計畫的熱情感到鼓舞。我們正努力在年底前獲得患者的臨床數據,並將利用這些數據以及來自患者和研究人員的回饋來指導下一步。展望2026年及以後,我們預計在技術精湛、積極進取且富有韌性的商業化團隊的支持下,公司將實現可持續的收入增長,滿足成人和兒童對口服HAE預防藥物的需求;另一款處於後期研發階段且進展順利的分子有望引領注射預防藥物市場;此外,我們的產品線中還包含針對罕見疾病的其他選擇,這些都將能夠創造為罕見疾病的價值。

  • With that, I'll turn it over to Bill to provide more color on our pipeline.

    接下來,我將把麥克風交給比爾,讓他為我們詳細介紹我們的管道系統。

  • William Sheridan - Chief Development Officer

    William Sheridan - Chief Development Officer

  • Thank you, Charlie. I'll cover our HAE programs to start with and then provide a brief update on our Netherton syndrome program. First, the Navenibart pivotal Phase III trial continues to recruit very well with strong enthusiasm for the study from investigators and potential trial patients. We expect to complete enrollment of the required 145 patients around the middle of 2026.

    謝謝查理。我先介紹我們的遺傳性血管性水腫(HAE)項目,然後再簡單報告內瑟頓症候群計畫的最新進展。首先,Navenibart的關鍵性III期臨床試驗的招募工作進展順利,研究人員和潛在的試驗患者都對這項研究表現出了極大的熱情。我們預計在2026年年中左右完成所需的145名患者的招募工作。

  • The primary efficacy analysis of the alpha-Orbit pivotal trial will be the comparison between each navenibart dosing regimen and placebo with the time-normalized rate of investigator-confirmed HAE attacks through 6 months. The Phase II efficacy and safety profile that we are reporting at Quad AI this weekend from the ALPHA-SOLAR Trial is excellent, with no safety signals in 29 patients through up to 24 months of dosing and a reduction from baseline in mean attack rates of 92% for every three-months of dosing and 90% for every six-months of dosing.

    alpha-Orbit關鍵性試驗的主要療效分析將比較每種navenibart給藥方案與安慰劑在6個月內經研究者確認的HAE發作時間標準化率方面的差異。我們本週末將在Quad AI大會上公佈ALPHA-SOLAR試驗的II期療效和安全性數據,結果非常出色。在29名患者中,長達24個月的給藥期間未出現任何安全訊號,平均發作率較基線每三個月降低92%,每六個月降低90%。

  • Overall, the mean attack rate decreased from 2.23 per month at baseline to 0.16 per month during navenibart treatment. For both dose regimens, the median attack rate reduction was 97%. These are outstanding results. These strong results illustrate the durability, consistency, and quality of treatment responses with navenibart and provide high confidence that the pivotal trial will be successful.

    總體而言,平均發作率從基線時的每月 2.23 次降至接受 navenibart 治療期間的每月 0.16 次。兩種劑量方案的中位發作率均降低了 97%。這些結果非常出色。這些強有力的結果表明 navenibart 治療反應具有持久性、一致性和高品質,並使我們高度相信這項關鍵性試驗將會成功。

  • We expect the pivotal trial results to confirm that navenibart every three-months or every six-months will set a new standard in the field and provide a very attractive choice for HAE patients seeking injectable prophylactic therapies. Second, we are thrilled that our application for ORLADEYO oral pellets for children aged 2 to less than 12 was approved by the FDA in December 2025.

    我們預期關鍵性試驗結果將證實,每三個月或每六個月注射一次navenibart將為該領域樹立新的標準,並為尋求注射預防性治療的HAE患者提供極具吸引力的選擇。其次,我們非常高興地宣布,我們用於2歲至12歲以下兒童的ORLADEYO口服顆粒劑的申請已於2025年12月獲得FDA批准。

  • We're now continuing with marketing authorization applications in other major regions with the goal of transforming treatment choice for patients, parents, and children with HAE around the world. Third, our clinical development program for our KLK5 inhibitor, Fc fusion protein BCX17725, in Netherton syndrome, has now moved into patient-focused research.

    我們目前正繼續在其他主要地區推進上市許可申請,​​目標是改變全球遺傳性血管性水腫(HAE)患者、家長和兒童的治療選擇。第三,我們針對內瑟頓症候群的KLK5抑制劑Fc融合蛋白BCX17725的臨床開發計畫現已進入以病人為中心的研究階段。

  • The healthy volunteer parts one and two of our Phase I trial with single and multiple ascending doses have been completed. BCX17725 was administered by subcutaneous and intravenous routes in these healthy volunteer cohorts. Our investigational drug was safe and well-tolerated. There were no discontinuations, no dose-related adverse findings, and no safety signals.

    我們已完成I期臨床試驗的第一部分和第二部分,這兩部分均採用單次和多次遞增劑量給藥方案,受試者為健康志願者。在這些健康志願者群組中,BCX17725分別透過皮下和靜脈途徑給藥。我們的研究藥物安全且耐受性良好。試驗期間無受試者中止,未發現與劑量相關的不良反應,也未出現任何安全訊號。

  • The top dose administered was 12 milligrams per kilogram every two weeks for three doses. And as noted in our last call, we were pleased to see evidence of the drug being distributed to the epidermis. Drug exposure was approximately linear in proportion to dose, and the estimated half-life was about 12 to 19 days, supporting continued study of every two-week administration schedules.

    最高給藥劑量為每公斤體重12毫克,每兩週一次,共三次。正如我們上次報告中所述,我們很高興地看到藥物已分佈至表皮。藥物暴露量與劑量呈近似線性關係,估計半衰期約為12至19天,這支持繼續研究每兩週一次的給藥方案。

  • Today, I'll provide a refresher on study design and an update on progress in the Netherton syndrome cohorts. The study design is outlined on slide 18. The patient cohorts in the study are open-label and designed to evaluate potential effects of the drug on clinical signs and symptoms of Netherton syndrome, as well as safety and drug exposure.

    今天,我將簡要回顧研究設計,並介紹內​​瑟頓症候群隊列研究的最新進展。研究設計概述請見第18張投影片。研究的患者群採用開放標籤設計,旨在評估藥物對內瑟頓症候群臨床徵兆和症狀的潛在影響,以及藥物的安全性和暴露。

  • There are two patient cohorts, a short-term administration cohort in Part 3 with four-weeks of dosing and a longer-term cohort in Part 4 with 12-weeks of dosing. Some sites were activated for Part 3 after short-term nonclinical safety studies were completed, and subsequently, were activated for Part 4, once we had longer-term nonclinical safety studies done.

    本研究包含兩個病患隊列:第三部分為短期給藥隊列,給藥週期為四周;第四部分為長期給藥隊列,給藥週期為十二週。部分研究中心在完成短期非臨床安全性研究後啟動了第三部分的研究,隨後在完成長期非臨床安全性研究後啟動了第四部分的研究。

  • We are prioritizing recruitment into Part 4 as this will give us a longer dosing experience, and we anticipate that no more than three patients will be entered into Part 3. Our clinical investigators are excited about the potential for this drug in Netherton syndrome and have identified patients who could be eligible. So, we expect to recruit up to 12 patients in Part 4 and generate results by the end of this year.

    我們優先招募第四部分試驗的患者,因為這將使我們獲得更長的給藥經驗,我們預計第三部分試驗的患者人數不會超過三人。我們的臨床研究人員對這種藥物在內瑟頓症候群治療的潛力感到興奮,並已確定了符合條件的患者。因此,我們預計第四部分試驗將招募至多 12 名患者,並在今年年底前得出結果。

  • For efficacy, the primary efficacy endpoint is change from baseline in the Ichtheosis Area and Severity Index, otherwise known as the IASI score, and key secondary endpoints include the Investigator Global Assessment score and the worst itch numerical rating scale score. We will also evaluate quality of life metrics. We intend to select doses and endpoints for a pivotal trial based on what we see in this Phase I trial.

    療效方面,主要療效終點為魚鱗病面積及嚴重程度指數(IASI)評分較基線的變化,關鍵次要終點包括研究者整體評估評分及最嚴重搔癢數值評分量表評分。我們還將評估生活品質指標。我們計劃根據本次 I 期試驗的結果,為關鍵性試驗選擇劑量和終點。

  • I'll now turn the call to Babar for the financial review.

    現在我將把電話轉給巴伯,請他進行財務審查。

  • Babar Ghias - Chief Financial Officer, Head of Corporate Development

    Babar Ghias - Chief Financial Officer, Head of Corporate Development

  • Thanks, Bill. Last year was a defining year for our company. We delivered strong top-line growth, record profitability, and reinforced our strong balance sheet position. Those results weren't just numbers. They were proof that our strategy is working and our operating model is built for scale. Before I turn to financials, I want to highlight that we are providing more clarity in our financials to enable a better understanding of the strength of our core business. Please refer to today's press release for our GAAP financial metrics.

    謝謝,比爾。去年對我們公司來說是意義非凡的一年。我們實現了強勁的營收成長、創紀錄的獲利能力,並鞏固了穩健的資產負債表。這些業績不僅僅是數字,它們證明了我們的策略行之有效,我們的營運模式也具備規模化發展的能力。在詳細介紹財務數據之前,我想強調的是,我們正在提高財務數據的透明度,以便大家更了解我們核心業務的優勢。請參閱今天發布的新聞稿,以了解我們採用美國通用會計準則(GAAP)編製的財務指標。

  • In my remarks, I will be referring to non-GAAP figures, which are adjusted for the sale of the European ORLADEYO business, stock-based comp, workforce reduction costs, and transaction-related costs. We believe that non-GAAP figures provide a clearer view of the business on a forward-looking basis. Our non-GAAP 2025 total revenue increased 45% year-on-year.

    在我的演講中,我將提及非GAAP財務數據,這些數據已根據出售歐洲ORLADEYO業務、股權激勵、裁員成本和交易相關成本進行了調整。我們認為,非GAAP財務數據能更清楚展現公司未來的發展前景。我們2025年的非GAAP總營收年增45%。

  • Since other revenues include contributions from Rapivab, which is non-core to our business, I would draw your attention to the non-GAAP ORLADEYO revenues, which increased by approximately $169 million or 43% year-on-year. This was a result of phenomenal day-to-day execution by our commercial team over the course of 2025.

    由於其他收入包含來自非核心業務Rapivab的貢獻,我想提請您關注非GAAP ORLADEYO收入,該收入年增約1.69億美元,增幅達43%。這得歸功於我們商業團隊在2025年期間卓越的日常執行力。

  • By leveraging our superior real-world evidence generation capabilities, we successfully drove higher patient volume and made significant progress on paid shipments. We have already started to see the impact of the European divestiture on our operating performance in Q4. Our non-GAAP operating profit jumped to $214 million, an increase of 198% year-on-year, the highest ever in BioCryst's history.

    憑藉我們卓越的真實世界證據產生能力,我們成功提升了患者數量,並在付費出貨方面取得了顯著進展。我們已經開始感受到歐洲業務剝離對第四季營運表現的影響。我們的非GAAP營業利潤飆升至2.14億美元,年增198%,創下BioCryst歷史新高。

  • R&D costs came down slightly in 2025 as we progress key programs while winding down some others and realigning the team structure. We anticipate that 2026 R&D costs will increase over 2025 as we complete the ongoing Phase III trial and BLA-enabling CMC activities for Novenibart. These activities, once complete, will naturally bring down development costs beyond 2026.

    2025年,隨著我們推進關鍵專案、逐步結束部分專案並調整團隊結構,研發成本略有下降。我們預計,隨著Novenibart正在進行的III期臨床試驗和生物製品許可申請(BLA)所需的CMC相關工作的完成,2026年的研發成本將高於2025年。這些工作完成後,自然會降低2026年以後的研發成本。

  • We will remain razor-focused on maintaining R&D spending discipline and allocating capital to high ROI opportunities. In the same spirit, we will quickly terminate programs that do not have a compelling path forward. Our sales and marketing expenses for the year were $144 million on a non-GAAP basis, which were primarily up due to some reallocation methodology, prelaunch costs for pediatrics, and higher specialty distribution fees and incentive comps naturally owing to the strong top-line growth.

    我們將繼續嚴格控制研發支出,並將資金投入高投資報酬率的項目。同時,對於缺乏明確發展路徑的項目,我們將迅速終止。本年度,我們的銷售和行銷費用(按非GAAP準則計算)為1.44億美元,主要成長原因是部分費用重新分配、兒科產品上市前成本,以及由於營收強勁增長而增加的專業分銷費用和激勵性薪酬。

  • More importantly, as you can calculate, for every dollar invested in our sales and marketing engine, we generated an approximately four times return on ORLADEYO net sales. While we do anticipate some small incremental annual expense tied to top-line growth, the ROI on ORLADEYO will continue to expand as we drive the business toward its blockbuster potential.

    更重要的是,正如您所計算的,我們在銷售和行銷方面每投入一美元,就能在 ORLADEYO 的淨銷售額上獲得約四倍的回報。雖然我們預計隨著營收成長,每年會產生一些小幅的額外支出,但隨著我們不斷推動業務朝著其爆款潛力邁進,ORLADEYO 的投資回報率將持續成長。

  • Looking further ahead to potential approval of Navenibart, the sales and marketing expense supporting our HAE franchise as a whole will be very stable, predictable, and carry an even greater ROI upside. We have built one of the best rare disease commercial organizations in the industry, a highly scalable infrastructure that will enable us to deliver multiple successful launches in the years to come in HAE and beyond, whether it's another candidate from our pipeline or something that we acquire in-license.

    展望Navenibart可能獲得批准的未來,我們整個HAE產品線的銷售和行銷費用將非常穩定、可預測,並帶來更大的投資報酬率。我們已建立起業內頂尖的罕見疾病商業化團隊,以及高度可擴展的基礎設施,這將使我們能夠在未來幾年內成功推出多個HAE及其他領域的產品,無論是我們研發管線中的新候選藥物,還是我們透過授權引進的藥物。

  • Driven by our strong operational results, we finished the year with a formidable liquidity position of $337.5 million in cash and investments on hand. Concurrent with the closing of the Astria acquisition, we entered into a highly attractive $400 million financing facility with Blackstone Life Sciences, a financial partner that is aligned with our vision of growth.

    得益於強勁的營運業績,我們年底的現金及投資儲備高達3.375億美元,流動性充裕。在完成對Astria的收購的同時,我們與Blackstone Life Sciences達成了一項極具吸引力的4億美元融資協議。 Blackstone Life Sciences是一家與我們發展願景高度契合的財務合作夥伴。

  • With the sustained momentum, coupled with the added benefit that now, for the next two-years, we will be able to utilize our prior period tax NOLs, we will be in a very strong cash flow-generating position. This will afford us optionality to evaluate a wide array of capital allocation strategies that reinforce durable value creation, be it M&A, debt paydown, or buybacks.

    憑藉持續的成長勢頭,再加上未來兩年我們可以利用前期稅項淨營業虧損(NOL),我們將擁有非常強勁的現金流。這將使我們能夠靈活評估各種資本配置策略,從而強化永續的價值創造,例如併購、償還債務或股票回購。

  • Moving on to guidance. We are maintaining expectations for full year 2026 ORLADEYO revenues to be between $625 million and $645 million, which at the midpoint represents approximately 13% growth over 2025 revenues adjusted for Europe. We expect full-year 2026 non-GAAP OpEx to be between $450 million and $470 million, which now includes expenses on Astria as previously guided.

    接下來是業績展望。我們維持對 ORLADEYO 2026 年全年營收的預期,預計在 6.25 億美元至 6.45 億美元之間,取中間值,較 2025 年經歐洲調整後的營收成長約 13%。我們預計 2026 年全年非 GAAP 營運支出將在 4.5 億至 4.7 億美元之間,其中已包含先前預期的 Astria 相關支出。

  • As Charlie emphasized, we remain very confident that ORLADEYO is on a solid footing to achieve blockbuster potential. We continue to see patient growth driven by the trends that we explained earlier, coupled with the recent pediatric approval, which will be an important component of the growth. After turning over this profitability card in 2025, we are very committed to staying profitable and continuing to drive cash flow generation going forward.

    正如查理所強調的那樣,我們仍然非常有信心,ORLADEYO 具備成為重磅藥物的堅實基礎。我們持續看到患者數量的成長,這得益於我們先前闡述的趨勢,以及近期兒科適應症的獲批,這將是成長的重要組成部分。在 2025 年實現盈利之後,我們致力於保持盈利,並持續推動現金流的成長。

  • To summarize, as we reflect on 2025, it is clear that the strength we delivered this past year is more than a financial milestone. It's a springboard for what comes next. We are entering 2026 with momentum, a sharpened competitive edge, and a discipline that ensures every investment we make is working towards value creation.

    總而言之,展望2025年,我們清楚地意識到,過去一年的成就遠不止於一個財務里程碑,它更是我們未來發展的跳板。我們帶著強勁的勢頭、更強大的競爭優勢以及嚴謹的作風邁入2026年,確保我們每一筆投資都能創造價值。

  • Our goal is to keep advancing our pipeline through both organic innovation and selective, disciplined BD that can expand our capabilities and accelerate our impact in the rare disease space. We are very excited to keep building the next growth phase of BioCryst, a company that not only performs quarter-to-quarter, but compounds value over the long term as we execute on that vision.

    我們的目標是透過內生創新和有選擇、有紀律的業務拓展,不斷推進產品線,從而提升自身能力,加速我們在罕見疾病領域的影響力。我們非常高興能夠繼續打造BioCryst的下一個成長階段,這家公司不僅能夠實現季度業績成長,而且隨著我們願景的實現,還能在長期內不斷創造價值。

  • Operator, we are now ready for your questions.

    操作員,我們現在可以回答您的問題了。

  • Operator

    Operator

  • (Operator Instructions) Laura Chico, Wedbush Securities.

    (操作員說明)勞拉‧奇科,韋德布希證券公司。

  • Laura Chico - Analyst

    Laura Chico - Analyst

  • I guess I wanted to start off on Navenibart. Could you talk a little bit more about the timing for the regulatory submission by year-end '27? Does that assume Phase III data still arriving by early '27? And I guess I just wanted to understand the steps that have to occur between top-line data and submission. And then, related to that, you mentioned the Quad AI late breaker.

    我想先談談Navenibart。能否詳細談談2027年底前提交監管申請的時間表?這是否意味著2027年初就能獲得第三期臨床試驗數據?我還想了解從初步資料到提交申請之間需要經歷哪些步驟。另外,您也提到了Quad AI這款後進者。

  • How should we think about this, I guess, in relation to ALPHA-STAR? It seems quite consistent in terms of the attack rate reductions. I'm wondering if there's incremental learning here, around maybe an attack-free period.

    我想,我們應該如何看待這個問題,尤其是在 ALPHA-STAR 的背景下?就攻擊率降低而言,它似乎相當穩定。我懷疑這其中是否存在某種漸進式學習機制,例如在一段無攻擊期之後。

  • Charles Gayer - President, Chief Executive Officer, Director

    Charles Gayer - President, Chief Executive Officer, Director

  • Thanks, Laura. Yes, we're clearly super excited about Navenibart. And yes, everything is on track for filing, such that we would be on track for filing by the end of next year. And so on track for approval by late 2028. Bill, do you want to answer the question just about the regulatory process?

    謝謝勞拉。是的,我們對Navenibart專案感到非常興奮。而且,所有申請流程都在按計劃進行,我們預計在明年年底前提交申請,並預計在2028年底前獲得批准。比爾,你願意回答一下關於監管流程的問題嗎?

  • William Sheridan - Chief Development Officer

    William Sheridan - Chief Development Officer

  • Sure. Like for other prophylactic therapies in HAE, 12-months is a chronic condition. You need 12-months of safety that will be delivered in mid-'27. And that's really what's driving the timing of the BLA submission. And what was the final question?

    當然。就像其他 HAE 預防性療法一樣,12 個月是一個慢性病程。你需要 12 個月的安全性數據,而這些數據將在 2027 年年中提供。這才是推動我們選擇這個時間提交生物製品許可申請 (BLA) 的真正原因。最後一個問題是什麼?

  • Charles Gayer - President, Chief Executive Officer, Director

    Charles Gayer - President, Chief Executive Officer, Director

  • And then the final question, just the data, yes, we're really excited about the data, the 92% reduction mean reduction for the three-month dose, the 90% for the 6-month dose, just shows incredible consistency. I think what's also really important is the mean attack rate of 0.16 across the population from their baseline. That's fewer than two attacks per year for patients plus the severity of the attacks went down as well. So for most of the year, patients are functionally attack-free, and that's what patients are looking for.

    最後一個問題,關於數據,是的,我們對數據非常滿意。三個月療程的平均降低幅度為92%,六個月療程的平均降低幅度為90%,展現了驚人的穩定性。我認為同樣重要的是,患者群體的平均發作率從基線水平降至0.16。這意味著患者每年發作次數少於兩次,而且發作的嚴重程度也降低了。因此,在一年中的大部分時間裡,患者實際上不會發作,而這正是患者所期望的。

  • Operator

    Operator

  • Brian Abrahams, RBC Capital Markets.

    Brian Abrahams,加拿大皇家銀行資本市場。

  • Brian Abrahams - Analyst

    Brian Abrahams - Analyst

  • Congrats on the continued strong progress. You talked a little bit about the ORLADEYO super responders staying on with good persistence for long periods of time. I guess, do you have any sense of how to predict who would be a super responder? And then just maybe along those lines, I'm curious how you envision positioning Navenibart in that context in terms of whether you push patients to switch to ORLADEYO?

    恭喜你們持續取得顯著進展。您剛才提到,對 ORLADEYO 療效顯著的患者能夠長期堅持治療。我想請問,您是否知道如何預測哪些患者會成為療效顯著的患者?另外,我還想了解一下,您打算如何定位 Navenibart,以及是否會鼓勵患者改用 ORLADEYO?

  • And then if they don't respond, Navenibart could be an option for them? Or would you be primarily positioning Navenibart for those 5,000 patients doing well on injectables who could use something that's less frequently dosed? Then, just maybe remind us of some of the aspects of the profile for Navenibart in terms of the number of injections, anti-drug antibodies, refrigeration requirements, just anything else that needs to be done with regards to formulation ahead of commercialization.

    如果患者沒有反應,Navenibart 是否可以作為他們的選擇?或者,Navenibart 的主要目標族群是那 5000 名註射治療效果良好的患者,他們需要一種給藥頻率較低的藥物?另外,能否請您簡單介紹 Navenibart 的一些特性,例如注射次數、抗藥性抗體、冷藏要求,以及上市前在製劑方面需要做的其他工作?

  • Charles Gayer - President, Chief Executive Officer, Director

    Charles Gayer - President, Chief Executive Officer, Director

  • Great. Thanks, Brian. I'll start, and then I'll have Bill answer some of those questions as well. As far as the predictability of the super responders in ORLADEYO, there really is no way to predict other than for patients to try. So, first of all, patients have to want to be on an oral, and we know that the majority of patients actually would prefer an oral.

    太好了,謝謝你,布萊恩。我先來,然後我也會請比爾回答一些問題。至於ORLADEYO研究中超級反應者的可預測性,除了讓病人嘗試之外,真的沒有其他方法可以預測。所以,首先,患者必須願意服用口服藥物,而且我們知道大多數患者實際上都更傾向於口服藥物。

  • But as we've looked at all of our clinical data, all the different factors, age, sex, prior prophy history, weight, everything else, there is nothing that can predict who is going to respond. As we know, HAE attacks are often driven by stress and other life factors. And so, I think our strategy is to try to get patients who are interested in oral to try.

    但是,當我們分析所有臨床數據,包括年齡、性別、先前預防史、體重等各種因素後,發現沒有任何因素可以預測哪些患者會有效。我們知道,遺傳性血管性水腫(HAE)發作通常由壓力和其他生活因素誘發。因此,我認為我們的策略是鼓勵對口服藥物有興趣的患者嘗試治療。

  • Most of them do great. We want them to do a thee- to six-month trial to really figure out if it's the right drug for them. And as we see, by a year, about 60% of them realize that it is the right drug for them. As far as the Navenibart positioning versus ORLADEYO, we see the primary opportunity for Navenibart to be those 5,000 patients on injectables.

    他們中的大多數人效果很好。我們希望他們進行為期三到六個月的試驗,以便真正確定這是否是適合他們的藥物。正如我們所看到的,一年後,大約 60% 的患者意識到這確實是適合他們的藥物。至於 Navenibart 與 ORLADEYO 的市場定位,我們認為 Navenibart 的主要市場機會在於那 5000 名正在接受注射治療的患者。

  • Like I said in my remarks, those patients are on injectables because they're doing well, but some of them are injecting 100-plus times a year. And so, to be able to do just two to four injections, we think, is going to be really compelling, and that's what we see in our patient research. So ORLADEYO then is going to be for patients who want to start prophy on oral, it's going to be the known, the trusted option with many years of data and experience.

    正如我剛才所說,這些患者之所以使用注射劑,是因為他們目前狀況良好,但有些患者一年要注射100多次。因此,我們認為,如果只需注射兩到四次,將會非常具有吸引力,而這正是我們在患者研究中看到的。所以,ORLADEYO 將適用於那些希望開始口服預防性治療的患者,它將成為經過多年數據和經驗累積的、值得信賴的選擇。

  • So ORLADEYO is for anyone who wants oral. Navenibart is for people who want an even better injectable positioning. And then for those patients who try ORLADEYO and it's not the drug for them, that also is an opportunity for Navenibart, all within the same BioCryst portfolio. For Navenibart, the number of injections is really going to be very simple.

    所以,ORLADEYO適用於任何想要口服藥物的患者。 Navenibart則適用於希望獲得更佳注射給藥體驗的患者。對於那些嘗試過ORLADEYO但感覺不適合自己的患者,Navenibart也是一個不錯的選擇,所有這些都屬於BioCryst的產品組合。 Navenibart的注射次數將非常簡單。

  • So, it's going to be launched with an auto-injector and the three-month dose after a 600-milligram loading dose, which will be 2 injections, 2 milliliter injections. The 3-month dose is then 1 injection. The 6-month dose is 2 injections. So very simple. And then, Bill, there was also a question just around ADAs and other things.

    所以,這款藥將採用自動注射器,在600毫克負荷劑量後,三個月的劑量需要注射兩次,每次2毫升。三個月的劑量只需注射一次。六個月的劑量需要注射兩次。非常簡單。另外,比爾,還有一個關於抗藥性抗體(ADA)和其他方面的問題。

  • William Sheridan - Chief Development Officer

    William Sheridan - Chief Development Officer

  • Yes. Before I get into that, with regard to predictability, I'll just reinforce what Charlie said. You have to try ORLADEYO to find out whether you're going to be a super responder. And so, it benefits people in every category with HAE. So, in addition to age, sex, race, weight, prophy exposure, you can also add to that whether you have a high attack rate or a low attack rate, whether it's less or more predictable, whether you have type 1 or type 2 HAE or C1 inhibitor normal HAE, all of those categories benefit.

    是的。在我深入探討之前,關於可預測性,我只想重申查理的說法。你必須嘗試使用ORLADEYO才能知道自己是否會成為超級反應者。因此,它對所有類型的HAE患者都有益處。所以,除了年齡、性別、種族、體重、預防性用藥史之外,你還可以加上你的發作頻率(高或低)、發作的可預測性(高或低)、以及你是1型、2型HAE還是C1抑制劑正常型HAE,所有這些因素都會使患者受益。

  • And we've shown that very definitively from both our clinical trials and our real-world evidence studies. So, you also asked about the maturity of the formulation development program for Navenibart. It's all done. It's very mature. CMC is in a great spot.

    我們已經透過臨床試驗和真實世界研究非常明確地證明了這一點。您也問到了Navenibart製劑開發專案的成熟度。這個項目已經全部完成,非常成熟。 CMC(化學、製造和控制)方面也進展順利。

  • Brian Abrahams - Analyst

    Brian Abrahams - Analyst

  • And then just a question about ADA?

    然後還有一個關於ADA的問題?

  • William Sheridan - Chief Development Officer

    William Sheridan - Chief Development Officer

  • With regard to ADA, there's no evidence of ADA impacting efficacy in the Phase II experience. And of course, with every biologic, it's part of the development program that you develop assays and look for ADAs; you always find them. What matters is whether people continue to benefit from the drug. And so far, that is exactly the case. There's no evidence of ADA impacting either safety or efficacy.

    關於抗藥性抗體(ADA),目前沒有證據顯示ADA會影響II期臨床試驗的療效。當然,對於任何生物製劑而言,開發檢測方法並尋找ADA都是研發流程的一部分;而且通常都會發現ADA。關鍵在於患者是否能持續從藥物中獲益。到目前為止,情況正是如此。沒有證據顯示ADA會影響藥物的安全性或療效。

  • Charles Gayer - President, Chief Executive Officer, Director

    Charles Gayer - President, Chief Executive Officer, Director

  • And just to remind folks, the data being presented this weekend, these are patients on Navenibart who out to as far as 24-months with a mean of about 12-months.

    再次提醒大家,本週末公佈的數據來自接受 Navenibart 治療的患者,治療時間最長可達 24 個月,平均約 12 個月。

  • William Sheridan - Chief Development Officer

    William Sheridan - Chief Development Officer

  • So, one last thing about the injections, they don't hurt.

    最後再補充一點,關於注射,它們並不痛。

  • Operator

    Operator

  • Steve Seedhouse, Cantor Fitzgerald.

    史蒂夫·西德豪斯,坎托·菲茨杰拉德。

  • Timur Ivannikov - Analyst

    Timur Ivannikov - Analyst

  • This is Timurvaniov on for Steve. For Neethererton, we just wanted to clarify, are you guys going to be releasing Part 3 and 4 data at the same time? And then also, could you talk about disease severity, the variability at baseline? Do you anticipate how difficult it would be to enroll more uniform patients? And then what background treatments are allowed, and how patients proceed based on their disease phenotype?

    這裡是蒂穆爾瓦尼奧夫,替史蒂夫發言。關於尼瑟頓,我們想確認一下,你們會同時發布第三部分和第四部分的數據嗎?另外,能否談談疾病的嚴重程度,以及基線時的變異性?你們預計招募更同質化的患者會有多困難?還有,允許使用哪些背景治療,以及患者如何根據其疾病表型進行後續治療?

  • Charles Gayer - President, Chief Executive Officer, Director

    Charles Gayer - President, Chief Executive Officer, Director

  • Okay. I'll start with just the Part 3 and 4, and then Bill can talk about the disease severity and the patient types. Our plan is to release all the data together. We're only going to have maybe 2 or 3 patients in Part 3. And as Bill said, we're now prepared across our sites to go into Part 4, and that 3-month dosing is what we think is really going to be meaningful. So we don't plan to do one patient at a time. We want to release a complete data set. And then Bill, just talk about the patients.

    好的。我先講第三部分和第四部分,然後比爾可以談談疾病嚴重程度和病人類型。我們的計劃是同時發布所有數據。第三部分可能只有兩到三名患者。正如比爾所說,我們所有研究中心都已準備好進入第四部分,我們認為三個月的給藥方案才是真正有意義的。所以我們不打算一次只納入一名患者。我們希望發布完整的資料集。然後比爾,你來談談患者的狀況。

  • William Sheridan - Chief Development Officer

    William Sheridan - Chief Development Officer

  • With regard to the spectrum of severity, there is one for sure, in Netherton syndrome. What we're finding from our research on the prevalence of disease, for example, is that, as Charlie said, it's underdiagnosed, and that's mostly because there are no approved treatments, but also because of the differences in severity from one patient to the next.

    就嚴重程度而言,內瑟頓症候群確實存在一個明確的譜系。例如,我們從對該疾病盛行率的研究中發現,正如查理所說,這種疾病被低估了,這主要是因為目前尚無核准的治療方法,但也因為不同患者的病情嚴重程度存在差異。

  • The patients we've met with this illness have obvious, really obvious disease, and they have adapted coping strategies. And that their lives have been dramatically impacted. That part of it, I'm not worried about in terms of recruiting subjects. So the investigators that we have that are lining up their subjects are more worried about getting spots for their subjects in the trial rather than not having enough patients to put in the trial.

    我們遇到的這些患有這種疾病的患者,他們的病情都非常明顯,而且他們也已經調整了應對策略。他們的生活受到了巨大的影響。就招募受試者而言,我並不擔心這方面的問題。所以,那些正在安排受試者的研究人員更擔心的是如何為他們的受試者爭取到試驗名額,而不是沒有足夠的病人參與試驗。

  • With regard to the eligibility, yes, we need to have evidence of illness so that we can identify whether there's a benefit from the drug. So we're doing that. We're selecting patients who have an obvious illness. And I think it will be fine. I'm not worried about that.

    關於入組資格,是的,我們需要有疾病證明,以便確定藥物是否有效。所以我們正在這樣做。我們選擇的是那些有明顯疾病的患者。我認為沒問題,我並不擔心。

  • Operator

    Operator

  • Maury Raycroft, Jeffries.

    莫里‧雷克羅夫特,傑弗里斯。

  • Unidentified Participant

    Unidentified Participant

  • This is [Amy] on for Maury. Congratulations on the quarter. Just a follow-up on a previous question. Can you provide more specifics on how you would provide updates and disclosure around the Navenibart program? And can you talk about your strategy to potentially get the FDA to accelerate the timelines?

    這裡是艾米,代表莫里。恭喜您本季取得佳績。我還有一個之前的問題需要跟進。您能否詳細說明您將如何提供關於Navenibart專案的最新資訊和揭露?您能否談談您爭取FDA加速審批進程的策略?

  • Charles Gayer - President, Chief Executive Officer, Director

    Charles Gayer - President, Chief Executive Officer, Director

  • Sure. So for Navenibart, as Bill mentioned, the enrollment is going well. And so we would probably update once we have the pivotal study fully enrolled. And then, sorry, what was the second part?

    當然。正如比爾所提到的,Navenibart 的招募工作進展順利。一旦關鍵性研究完成全部招募,我們可能會更新資訊。對了,第二部是什麼來著?

  • William Sheridan - Chief Development Officer

    William Sheridan - Chief Development Officer

  • The second part is about doing our best to pull that forward as this program matures; that's obviously something we'll be focused on. So, for example, elements of the BLA that we can start writing, we'll start to write. We won't have a crystal clear understanding of the timing of the BLA until two things happen. And one is the last patient's first visit, so that we can predict when the last visit is for 12-months later, obviously.

    第二部分是關於隨著專案日趨成熟,我們將盡最大努力推進這項工作;這顯然是我們關注的重點。例如,我們可以開始撰寫生物製品授權申請(BLA)中的一些內容。在兩件事發生之前,我們無法完全確定BLA的提交時間。一是最後一位患者的首次就診時間,這樣我們才能預測12個月後的最後一次就診時間。

  • The next step is getting clarity with the division at a pre-BLA meeting on the total content of the BLA. And obviously, that comes later. So I think we'll be able to provide more clarity in due course.

    下一步是在生物製品授權協議 (BLA) 簽署前的會議上與相關部門明確 BLA 的全部內容。當然,這要等到以後才會進行。所以我認為我們會在適當的時候提供更清晰的資訊。

  • Operator

    Operator

  • Jon Wolleben, Citizens.

    Jon Wolleben,市民。

  • Unidentified Participant

    Unidentified Participant

  • This is [Catherine] on for Jon. I just have a quick question about whether you guys are seeing any impact from the recent new entrants, including the oral acute therapies, and whether any patients are switching to ORLADEYO? Are you seeing differences in the reasons for patients switching? I know there's not really been much of an impact on revenues, but if you expect any impact or if you're starting to see it at all? Any color on that?

    我是凱瑟琳,替喬恩提問。我有個問題想問你們,最近新上市的藥物,包括口服急性治療藥物,對你們的業績有什麼影響嗎?有沒有病人轉而使用ORLADEYO?患者轉用藥物的原因有什麼不同嗎?我知道目前對收入的影響還不大,但你們預期會有影響嗎?或是已經開始看到影響了嗎?有什麼具體情況可以分享嗎?

  • Charles Gayer - President, Chief Executive Officer, Director

    Charles Gayer - President, Chief Executive Officer, Director

  • Sure, Catherine. As we've said, particularly a lot last year leading up to new entrants coming in, we did not expect there to be an impact on ORLADEYO from new prophy entrants because there's a real difference between patients who want oral prophy and then patients who are more comfortable with injectables. So we expected the injectables to be competing more with existing injectables, and that's what we're seeing.

    當然,凱瑟琳。正如我們之前所說,尤其是在去年新品牌進入市場之前,我們預計新的口腔清潔產品不會對ORLADEYO造成影響,因為選擇口腔清潔的患者和更傾向於注射清潔的患者之間存在著顯著差異。因此,我們預期注射清潔產品之間的競爭會更加激烈,而事實也正是如此。

  • So it's not changing ORLADEYO prescribing patterns or patient patterns in general. As far as oral on-demand, oral acute therapy, that's something we're certainly not seeing affect ORLADEYO negatively in any way. We think over time, there is a potential for a tailwind of just patients who want to be in an all oral combination, so one pill once a day to prevent attacks and then for the occasional breakthrough attacks, treat with another oral, that's a great opportunity for many patients. But it's too early to say whether that tailwind is going to occur.

    因此,這不會改變 ORLADEYO 的處方模式或患者的整體用藥習慣。至於按需口服和口服急性治療,我們目前尚未發現這對 ORLADEYO 產生任何負面影響。我們認為,隨著時間的推移,可能會出現一種利好趨勢,即部分患者希望採用全口服組合療法,每天服用一片藥來預防發作,然後針對偶爾出現的突破性發作,再服用另一種口服藥物進行治療。這對許多患者來說是一個很好的選擇。但現在斷言這種利好趨勢是否會出現還為時過早。

  • Operator

    Operator

  • Serge Belanger, Needham & Company.

    Serge Belanger,Needham & Company。

  • John Todaro - Analyst

    John Todaro - Analyst

  • This is John on for Serge today. First, just on ORLADEYO. You guys took a 9% price increase in January. Beyond that, curious which levers you'll be looking at most closely in '26, whether it be maintaining trends of new patient adds or making slight improvements on paid prescription rates, either in Medicare or commercial channels.

    我是John,今天替Serge為您報道。首先,我們來聊聊ORLADEYO。你們一月漲價了9%。除此之外,我很好奇你們在2026年最關注哪些方面,是維持新增病患數量的成長勢頭,還是在醫保或商業管道中略微提高付費處方藥的收費率。

  • And then on the pellet formulation for pediatrics, curious how we should think about the pacing of patient identification and conversion throughout '26. And does your current guidance assume any material contribution from this segment this year?

    關於兒科用顆粒劑配方,我很好奇我們應該如何考慮2026年全年患者識別和轉化的進度。您目前的指導意見是否假設今年該領域會有任何實質貢獻?

  • Charles Gayer - President, Chief Executive Officer, Director

    Charles Gayer - President, Chief Executive Officer, Director

  • Great. Thanks, John. Yes, we did take up a 9% price increase in early January, which is higher than we've done in the past. We'll net about half of that, so about 4.5%. So that is something more because ORLADEYO was a lot lower priced than most of the other products in the market. And so this was just a little bit of a catch-up, but not something that we need that kind of pricing going forward to get to our long-term peak of $1 billion.

    太好了,謝謝約翰。是的,我們在1月初確實漲價了9%,這比以往都要高。我們最終能收回大約一半的成本,也就是4.5%左右。這主要是因為ORLADEYO的價格之前遠低於市場上大多數其他產品。所以這次漲價只是為了追趕市場,但我們並不需要一直維持這樣的物價水準才能達到10億美元的長期目標。

  • For this year, the KPI that is most important to us is net patient growth. And as we've said, and it's in our slides today, what we need is 150 patients net patient growth average per year for this year and three more years to hit $1 billion in 2029. So we are very much within sight of getting to that $1 billion. And so that's the number one thing. Of course, we're always working to improve the paid rate incrementally.

    今年對我們來說最重要的關鍵績效指標是淨患者成長。正如我們今天在幻燈片中提到的,我們需要在今年及未來三年內平均每年淨增長150名患者,才能在2029年實現10億美元的目標。因此,我們距離10億美元的目標已經非常接近了。所以,這是我們的首要任務。當然,我們也一直在努力逐步提高付費率。

  • We made a big jump in the last year. And now it's just about making incremental improvements, and we're using our real-world evidence. So, for example, in patients with normal C1 inhibitor, we're starting to see more plans adopt favorable coverage policies for this based on the real-world evidence that we're providing. So that's a constant process.

    去年我們取得了長足的進步。現在,我們的目標是穩步提升,並充分利用真實世界數據。例如,對於C1抑制劑水平正常的患者,我們開始看到越來越多的醫療保險計劃根據我們提供的真實世界數據,制定了更有利的報銷政策。這是一個持續的過程。

  • Then, for the pellets, one of the things I mentioned in my remarks is that HAE is underdiagnosed in kids. We found about 500 patients in claims data for kids under age 12. But statistically, based on the epidemiology, there should be 1,200. And one of the reasons is parents are sometimes reluctant to get their kids tested because they're frankly hoping their kids don't have HAE.

    關於植入物,我剛才提到的一點是,兒童遺傳性血管性水腫(HAE)的診斷率偏低。我們在理賠數據中發現,12歲以下兒童的HAE患者約有500例。但根據流行病學統計,實際患者人數應該有1200例。其中一個原因是,有些家長不願意讓孩子接受檢查,因為他們其實希望自己的孩子沒有患有HAE。

  • But the availability of an oral therapy, we think, and we've seen this in the early days of the HAE market, having a therapy encourages diagnosis. So there's a market growth opportunity. And then kids are only treated with prophy at about a 40% rate, which is half that of adults. And so there's a potential to up to double the number of kids diagnosed and up to double the treatment rate.

    但我們認為,口服療法的出現(我們在HAE市場早期就已經看到這一點),能夠促進診斷。因此,市場存在成長機會。目前,兒童接受預防性治療的比例僅40%左右,是成人的一半。因此,兒童確診人數和治療率都有可能翻倍。

  • And we think that an oral prophy is the thing to do. Then, as far as guidance, yes, the peads launch is in our guidance for this year, but it's a really small part. We are very bullish long-term on what this indication is going to mean for kids and for revenue. But what we don't know is how quickly that transformation is going to happen. And so we've been conservative in our thinking for this year. And then we'll see how it goes. But if it goes faster than we expect, it could be a tailwind.

    我們認為口腔清潔是必要的。至於業績指引,兒科產品的上市確實在我們今年的業績指引中,但這只佔很小一部分。我們對這種適應症的長期前景非常樂觀,認為它將為兒童和公司帶來巨大的收入成長。但我們無法預測這種轉變會以多快的速度發生。因此,我們今年的計畫比較保守。之後我們會觀察市場發展。但如果進展速度超出預期,可能會對我們有利。

  • Operator

    Operator

  • (Operator Instructions) Vishwesh Shah, TD Cowen.

    (操作說明)Vishwesh Shah,TD Cowen。

  • Vishwesh Shah, Ph.D. - Analyst

    Vishwesh Shah, Ph.D. - Analyst

  • This is Vish on for Stacy. Congratulations on a great year, and I really appreciate your comments on the competitive dynamics. We have a couple. So first, for ORLADEYO, expectations for Q1. Can you give us an idea of how the reauthorization process is progressing this year? We know you made some improvements in the process last year, which resulted in faster-than-expected reauthorizations.

    這裡是Vish,替Stacy問話。恭喜您度過了精彩的一年,非常感謝您對競爭格局的見解。我們有幾個問題。首先,關於ORLADEYO,您對第一季的預期是什麼?能否介紹一下今年的重新授權流程進度如何?我們知道您去年對流程進行了一些改進,使得重新授權的速度比預期更快。

  • So just walk us through what you're seeing and what we, and investors, should expect for Q1? Then, second and final for us, given the EU business sale, are you willing to split your 2026 guidance for US and ex-US contributions? How should we be thinking about that?

    那麼,請您詳細介紹一下您目前觀察到的情況,以及我們和投資人對第一季的預期?其次,也是最後一個問題,考慮到歐盟業務的出售,您是否願意將2026年的業績指引拆分為美國和美國以外地區的貢獻?我們該如何看待這個問題?

  • Charles Gayer - President, Chief Executive Officer, Director

    Charles Gayer - President, Chief Executive Officer, Director

  • Great. Thanks, Vish. I'll take the first question and pass it over to Babar for the second question. Every Q1 is the big reauthorization season. It's a ton of work. Our team prepares for it. They're right in the midst of that process, and our team has gotten really good at it. What you should expect for Q1, because this year, we don't have any huge tailwind like we did last year with the Medicare patients and the IRA, making it more affordable for patients.

    太好了,謝謝Vish。我先回答第一個問題,第二個問題交給Babar。每年第一季都是重新授權的大旺季,工作量龐大。我們的團隊為此做好了充分的準備,他們現在正全力投入這項工作中,而我們團隊在這方面已經累積了豐富的經驗。至於第一季的情況,由於今年不像去年那樣有Medicare患者和IRA(個人退休帳戶)帶來的巨大利好,導致患者更容易負擔醫療費用,所以大家需要做好心理準備。

  • The Medicare patients are in great shape. So we won't have that tailwind. So this year, you should expect revenue probably to be slightly down versus Q4 as we go through the reaff. We have to give away more free product. We have to pay a higher percentage of co-pays for the commercial patients. And so that drops revenue even as our patient base continues to grow. So down a bit in Q1 and then it pops up again in Q2. And Babar, do you want to just talk about the US versus global?

    聯邦醫療保險(Medicare)的患者情況良好,所以我們不會有這方面的利多。因此,今年由於疫情影響,預計收入會比第四季略有下降。我們需要發放更多免費產品,也要為商業保險患者支付更高比例的自付費用。即使我們的患者群體持續成長,這些因素也會導致收入下降。所以第一季會略有下降,然後第二季會回升。巴伯,你想單獨談談美國市場和全球市場的情況嗎?

  • Babar Ghias - Chief Financial Officer, Head of Corporate Development

    Babar Ghias - Chief Financial Officer, Head of Corporate Development

  • With respect to your question on the costs and contributions from Europe, if you look at our press release in the financial tables, we actually attempted to break out all that European business. I think, as we have previously stated, that European business, while growing, was also loss-making. So you can actually see that our base business margins were incredibly strong compared to the US.

    關於您提到的歐洲業務的成本和貢獻問題,如果您查看我們新聞稿中的財務表格,您會發現我們實際上已經嘗試將所有歐洲業務單獨列出。正如我們之前所述,歐洲業務雖然在成長,但同時也處於虧損狀態。因此,您可以清楚地看到,與美國業務相比,我們的基礎業務利潤率非常高。

  • The US business margins are incredibly strong compared to Europe. So when you look at that profitability metric that I quoted, the $214 million, that strips out all of Europe. And from the exhibits, you can glean that the base business costs are $380 million for the US in 2025. To give you a perspective on what it looks like in 2026, and this goes back to the same cost discipline, we shut off Europe, but we added a very, very highly derisked late-stage program in Navenibart.

    與歐洲相比,美國業務的利潤率非常高。所以,當我提到我之前提到的2.14億美元的獲利指標時,這已經剔除了歐洲的全部業務。從圖表中可以看出,2025年美國業務的基本成本為3.8億美元。為了讓您更了解2026年的情況(這同樣是為了控製成本),我們關閉了歐洲業務,但同時在Navenibart新增了一個風險極低的後期研發專案。

  • So our total costs are in the $450 million to $470 million range, of which the base business is actually not growing by much. The cost additions are primarily coming from adding Astria. So that's the discipline that I talked about that we will continue to make sure that our base business costs remain low, and we continue to drive growth. I hope that answers your question.

    因此,我們的總成本在 4.5 億美元到 4.7 億美元之間,其中基礎業務的成本成長並不顯著。成本增加主要來自收購 Astria。這就是我之前提到的,我們將繼續確保基礎業務成本保持在較低水平,並持續推動成長。希望我的回答能解答您的問題。

  • Vishwesh Shah, Ph.D. - Analyst

    Vishwesh Shah, Ph.D. - Analyst

  • Yes. My question was relating to the 2026 guidance, the $625 million to $645 million that we're expecting for this year. How should we think about the US and ex-US split there?

    是的。我的問題是關於2026年的業績指引,也就是我們預計今年的6.25億美元至6.45億美元。我們該如何看待美國本土和非美國本土的業績劃分?

  • Babar Ghias - Chief Financial Officer, Head of Corporate Development

    Babar Ghias - Chief Financial Officer, Head of Corporate Development

  • Yes. So a majority of that is going to be from the US We have retained some markets. And as you can see, after Europe, the split is now it's a little bit over 90%. So, while we're not breaking out, the majority of that is coming from the US business.

    是的。所以大部分收入將來自美國。我們保留了一些市場。正如你所看到的,歐洲市場之後,美國市場的佔比現在略高於90%。因此,雖然我們還沒有完全獲利,但大部分收入確實來自美國業務。

  • Operator

    Operator

  • This concludes our question-and-answer session. I would like to turn the conference back over to Charlie Dyer for any closing remarks.

    問答環節到此結束。現在我把會議交還給查理·戴爾,請他作總結發言。

  • Charles Gayer - President, Chief Executive Officer, Director

    Charles Gayer - President, Chief Executive Officer, Director

  • Thanks very much. 2026, as we've been describing, is a really big year for BioCryst. We've got continued ORLADEYO patient growth. We're super excited about the launch of ORLADEYO for kids. A lot of important clinical trial execution for Novenibart and 17725 is going well. And I'd really like to thank all the hard-working owners at BioCryst for what they did to make 2025 a great year and what they're doing this year to deliver another year of great results. So thanks, everyone. Have a great day.

    非常感謝。正如我們之前所說,2026年對BioCryst來說意義非凡。 ORLADEYO的患者數量持續成長。我們對ORLADEYO兒童版的上市感到無比興奮。 Novenibart和17725的多項重要臨床試驗進展順利。我衷心感謝BioCryst所有辛勤工作的股東,感謝他們為2025年的輝煌成就所做的貢獻,也感謝他們今年為再創佳績所做的努力。謝謝大家!祝大家今天愉快!

  • Operator

    Operator

  • The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

    會議已結束。感謝您參加今天的報告。您可以斷開連線了。